CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

DATA COMPILATION
#PharmaFlow

Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

Stock Recap
#PipelineProspector

Memantine HCL (2)

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

101 API Suppliers, 33 USDMF, 3 CEP/COS, 11 JDMF, 14 EU WC, 33 KDMF, 27 NDC API, 44 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

28 Drugs in Development

28 Drugs in Development

INTERMEDIATES

14 Intermediate Suppliers

14 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

641 FDF Dossiers, 129 FDA Orange Book, 402 Europe, 12 Canada, 14 Australia, 9 South Africa, 75 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG, TABLET;ORAL - 5MG, CAPSULE, EXTENDED RELEASE;ORAL - 14MG, CAPSULE, EXTENDED RELEASE;ORAL - 21MG, CAPSULE, EXTENDED RELEASE;ORAL - 28MG, CAPSULE, EXTENDED RELEASE;ORAL - 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 2 Rochem International Inc, 8 SPI Pharma, 1 Pharm-RX Chemical, 5 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 8 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Pfanstiehl, 4 Kirsch Pharma, 1 Panvo Organics, 1 Cerata Pharmaceuticals LLP, 7 Dr. Paul Lohmann GmbH & Co. KGaA, 4 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 1 Avesta Pharma, 26 BASF, 1 Bioplus Life Sciences, 1 CD Formulation, 2 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 1 Gloria Interchem, 5 Ideal Cures, 4 Ingredion Pharma Solutions, 1 JJ Chemicals, 25 Kerry, 3 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 12 Microlex e.U, 1 Neelkanth MineChem, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 8 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

68 Fillers, Diluents & Binders, 52 Coating Systems & Additives, 31 Direct Compression, 31 Controlled & Modified Release, 31 Granulation, 28 Disintegrants & Superdisintegrants, 26 Thickeners and Stabilizers, 25 Film Formers & Plasticizers, 24 Lubricants & Glidants, 23 Topical, 20 Taste Masking, 20 Solubilizers, 18 Parenteral, 14 Co-Processed Excipients, 12 API Stability Enhancers, 10 Chewable & Orodispersible Aids, 9 Empty Capsules, 7 Emulsifying Agents, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 2 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 86 News #PharmaBuzz

GLOBAL SALES INFORMATION

34 US Medicaid Prescriptions, 46 Regulatory FDF Prices, 12 Annual Reports

MARKET PLACE

17 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 1 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 23 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
31/03/2026	Megafine Pharma (P) Limited	India	MEGAFINE PHARMA PRIVATE LIMITED Mumbai IN	CEP 2025-233 - Rev 00	Memantine hydrochloride	2026-03-25	Valid	Chemical		2773
31/03/2026	MSN Laboratories	India	MSN PHARMACHEM PRIVATE LIMITED Sangareddy District IN	CEP 2025-237 - Rev 00	Memantine hydrochloride, Crystalline Form-I, Micronised and Non-micronised	2025-11-24	Valid	Chemical		2773

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Memantine HCL (2)

Memantine HCL (2)

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

101 API Suppliers

33 USDMF

3 CEP/COS

11 JDMF

14 EU WC

33 KDMF

27 NDC API

44 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

28 Drugs in Development

INTERMEDIATES

14 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

641 FDF Dossiers

129 FDA Orange Book

402 Europe

12 Canada

14 Australia

9 South Africa

75 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG

TABLET;ORAL - 5MG

CAPSULE, EXTENDED RELEASE;ORAL - 14MG

CAPSULE, EXTENDED RELEASE;ORAL - 21MG

CAPSULE, EXTENDED RELEASE;ORAL - 28MG

CAPSULE, EXTENDED RELEASE;ORAL - 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

2 Rochem International Inc

8 SPI Pharma

1 Pharm-RX Chemical

5 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 Pfanstiehl

4 Kirsch Pharma

1 Panvo Organics

1 Cerata Pharmaceuticals LLP

7 Dr. Paul Lohmann GmbH & Co. KGaA

4 ACG Worldwide

8 Actylis

1 Aeon Procare

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

1 Avesta Pharma

26 BASF

1 Bioplus Life Sciences

1 CD Formulation

2 Clariant

11 Corel Pharma Chem

7 DFE Pharma

1 Esteem Industries

2 Finar

9 Gangwal Chemicals

1 Gloria Interchem

5 Ideal Cures

4 Ingredion Pharma Solutions

1 JJ Chemicals

25 Kerry

3 Keval Exports

4 Kima Chemical

6 Lonza Capsugel

12 Microlex e.U

1 Neelkanth MineChem

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

CAPSULE, EXTENDED RELEASE;ORAL - 7MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons